Lundbeck Q3 2019 Financial Results

Selected deliverables for 2019 * Start PoC study on Lu AF11167 in schizophrenia Commence the launch of Rxulti/Rexulti in Europe * Pivotal data for Rexulti in bipolar mania * Headline results (POC) for foliglurax in Parkinson's (delayed to H1 2020) * Continue LCM activities on brexpiprazole 3 * Obtain approval of Trintellix in Japan * Achieve FIH in 1-2 R&D projects * Execute on Expand and Invest to Grow 49 Lundbeck

View entire presentation